戈舍瑞林联合内分泌药物对绝经前晚期乳腺癌患者疗效评估  

Curative Effects of Goserelin Combined with Endocrine Drugs on Premenopausal Patients with Advanced Breast Cancer

作　　者：王洪涛[1] 黄远丽[1] 杨远荣[1] 李华荣[1] 王振军[1] 任华益[2] 

机构地区：[1]华中科技大学同济医学院附属荆州医院,湖北荆州434020 [2]中南大学湘雅医学院附属肿瘤医院,湖南长沙410013

出　　处：《现代生物医学进展》2016年第31期6091-6093,共3页Progress in Modern Biomedicine

基　　金：湖南省卫生厅科技计划项目(B2012-091)

摘　　要：目的:研究戈舍瑞林联合内分泌药物对绝经前晚期乳腺癌患者疾病进展的作用效果及生存率的影响作用。方法:回顾性分析绝经前晚期乳腺癌患者157例,其中78例住院期间服用戈舍瑞林作为对照组,79例采用戈舍瑞林联合内分泌药物治疗作为治疗组;对比两组患者住院期间的疾病进展状况及生存率情况。结果:两组患者标准治疗过程中数据资料比较不存在差异性(P>0.05);治疗后,治疗组患者疾病进展情况明显高于对照组,在不同时间段内组间比较差异有统计学意义(P<0.05);随访一年结果显示患者复发、生活质量及死亡例数情况组间对比,其中复发、生活质量为优及死亡例数情况组间比较差异均有统计学意义(P<0.01)。结论:戈舍瑞林结合内分泌药物对于绝经前晚期乳腺癌患者的疾病进展具有良好的控制作用。Objective： To study the effects of goserelin combined with endocrine drugs on disease progression and survival of premenopausal advanced breast cancer patients. Methods： We retrospectively analyzed the data of 157 cases of premenopausal advanced breast cancer patients in our hospital. Among them, 78 patients had goserelin during hospitalization were taken as control group, and another 79 patients taking goserelin and endocrine drugs in combination regimens as treatment group. Compare the disease progression during hospitalization and survival situation between two groups. Results： There were no differences in data during the course of standard treatment between groups（P〉0.05）. After treatment, the breast cancer disease progression were significantly better in the treatment group than in the control group, and differences between different time groups had statistical significance（P〈0.05）. In the one-year follow up,there were differences in the reoccurrence, cases with life quality classified as excellent and death cases between the two groups（P 〈0.01）. Conclusion： The combination of goserelin and endocrine drugs has good progression control effect for patients with advanced breast cancer before menopause.

关 键 词：戈舍瑞林 内分泌药物 TAM 晚期乳腺癌 生存率 

分 类 号：R737.9[医药卫生—肿瘤]